Bea Jennifer W, Wassertheil-Smoller Sylvia, Wertheim Betsy C, Klimentidis Yann, Chen Zhao, Zaslavsky Oleg, Manini Todd M, Womack Catherine R, Kroenke Candyce H, LaCroix Andrea Z, Thomson Cynthia A
University of Arizona Cancer Center, 1515 N. Campbell Ave, P.O. Box 245024, Tucson, AZ 85724-0524, USA.
Department of Epidemiology and Population Health, Albert Einstein College of Medicine of Yeshiva University, 1300 Morris Park Avenue, Belfer Building, Room 1308B, Bronx, NY 10461, USA.
J Aging Res. 2018 Feb 19;2018:8491092. doi: 10.1155/2018/8491092. eCollection 2018.
Studies suggest that ACE-inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) may preserve skeletal muscle with aging. We evaluated longitudinal differences in lean body mass (LBM) among women diagnosed with hypertension and classified as ACE-I/ARB users and nonusers among Women's Health Initiative participants that received dual energy X-ray absorptiometry scans to estimate body composition (=10,635) at baseline and at years 3 and 6 of follow-up. Of those, 2642 were treated for hypertension at baseline. Multivariate linear regression models, adjusted for relevant demographics, behaviors, and medications, assessed ACE-I/ARB use/nonuse and LBM associations at baseline, as well as change in LBM over 3 and 6 years. Although BMI did not differ by ACE-I/ARB use, LBM (%) was significantly higher in ACE-I/ARB users versus nonusers at baseline (52.2% versus 51.3%, resp., =0.001). There was no association between ACE-I/ARB usage and change in LBM over time. Reasons for higher LBM with ACE-I/ARB use cross sectionally, but not longitundinally, are unclear and may reflect a threshold effect of these medications on LBM that is attenuated over time. Nevertheless, ACE-I/ARB use does not appear to negatively impact LBM in the long term.
研究表明,血管紧张素转换酶抑制剂(ACE-I)和血管紧张素受体阻滞剂(ARB)可能随着衰老过程保护骨骼肌。我们评估了女性健康倡议参与者中被诊断为高血压且分为ACE-I/ARB使用者和非使用者的女性之间瘦体重(LBM)的纵向差异,这些参与者在基线以及随访的第3年和第6年接受了双能X线吸收法扫描以估计身体成分(n = 10,635)。其中,2642人在基线时接受高血压治疗。多变量线性回归模型在调整了相关人口统计学、行为和药物因素后,评估了基线时ACE-I/ARB的使用/未使用情况与LBM的关联,以及3年和6年期间LBM的变化。尽管BMI在ACE-I/ARB使用者和非使用者之间没有差异,但在基线时,ACE-I/ARB使用者的LBM(%)显著高于非使用者(分别为52.2%和51.3%,P = 0.001)。ACE-I/ARB的使用与LBM随时间的变化之间没有关联。ACE-I/ARB使用导致LBM在横断面时较高但在纵向时并非如此的原因尚不清楚,可能反映了这些药物对LBM的阈值效应,这种效应会随着时间减弱。然而,从长期来看,ACE-I/ARB的使用似乎不会对LBM产生负面影响。